Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Clement Douault

John Liddle

David Matthew Wilson

Michael David Barker

Neil Stuart Garton

Ann Louise Walker

Stephen John Atkinson

Christopher Roland Wellaway

Matthew Campbell

Robert John Sheppard

Hawa Diallo

Dominique Amans

Jessica Fanny Renaux

Vipulkumar Kantibhai Patel

Francis Louis Atkinson

Alexander George Steven Preston

Christopher Wellaway

Compounds of formula (I): wherein X, Y, Rand R-Rare as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis. 

Benzoimidazole derivatives as PAD4 inhibitors

Compounds of formula (I) wherein; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl-O&#x2014;, or Calkoxy; Ris hydrogen, Calkyl, or CalkoxyCalkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl; or unsubstituted CcycloalkylCalkyl; A is C&#x2014;Ror N; B is C&#x2014;Ror N; D is C&#x2014;Ror N; with the proviso that at least one of A, B, and D, is N; Ris hydrogen or Calkyl; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, Calkoxy, or hydroxy; Ris hydrogen or Calkyl, with the proviso that one of Rand Ris hydrogen; Ris hydrogen or hydroxy; Ris hydrogen or Calkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors

Compounds of formula (I) wherein; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl-O&#x2014;, or Calkoxy; Ris hydrogen, Calkyl, or CalkoxyCalkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl; or unsubstituted CcycloalkylCalkyl; A is C&#x2014;Ror N; B is C&#x2014;Ror N; D is C&#x2014;Ror N; with the proviso that at least one of A, B, and D, is N; Ris hydrogen or Calkyl; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, Calkoxy, or hydroxy; Ris hydrogen or Calkyl, with the proviso that one of Rand Ris hydrogen; Ris hydrogen or hydroxy; Ris hydrogen or Calkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis. 

2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors

2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors

The present invention relates to a compound of formula (I): or a salt thereof;which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.

7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors

Growing community of inventors

Stevenage, United Kingdom

Clement Douault